Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
Healthcentric Advisors · Talbot & Talbot (South Africa) · +9 more institutions
Abstract
The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews." At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing…
Citation impact
- FWCI
- 86.32
- Percentile
- 100%
- References
- 81
Authors
6- GHGeorge H. TalbotCorresponding
Healthcentric Advisors, Talbot & Talbot (South Africa)
- JSJohn S. Bradley
Rady Children's Hospital-San Diego
- JEJohn E. Edwards
University of California, Los Angeles, The Lundquist Institute, Los Angeles Medical Center
- DNDavid N. Gilbert
Providence Portland Medical Center, Oregon Health & Science University
- MSMichael Scheld
University of Virginia
Topics & keywords
- Legislature
- Medicine
- Public health
- Antimicrobial
- Task force
- Infectious disease (medical specialty)
- Intensive care medicine
- Public relations